Forte Biosciences (FBRX) Non Operating Income (2016 - 2018)
Forte Biosciences (FBRX) posted quarterly Non Operating Income of -$762000.0 for Q2 2018, down 84.06% year-over-year from -$4.8 million in Q2 2017, and down 2141.18% quarter-over-quarter from -$34000.0 in Q1 2018.
Powered by 
Analysis
Forte Biosciences (FBRX) Non Operating Income (2016 - 2018) Analysis & Trends
Forte Biosciences (FBRX) has reported Non Operating Income for 3 consecutive years, with -$762000.0 the latest figure, recorded in Q2 2018.
- In Q2 2018, Non Operating Income fell 84.06% year-over-year to -$762000.0; the TTM figure through Jun 2018 stood at -$1.2 million (up 37.49% YoY), while the FY2025 annual figure was $2.3 million, up 106.32% from the prior year.
- Non Operating Income fell to -$762000.0 in Q2 2018 per FBRX's latest filing, from -$34000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at -$34000.0 in Q1 2018 and bottomed at -$762000.0 in Q2 2018.
- Historically, Non Operating Income has averaged -$388300.0 across 3 years, with a median of -$431000.0 in 2016.
- On a YoY basis, Non Operating Income climbed as much as 93.46% in 2018 and fell as far as 84.06% in 2018.
- Forte Biosciences' Non Operating Income stood at -$456000.0 in 2016, then surged by 67.11% to -$150000.0 in 2017, then tumbled by 408.0% to -$762000.0 in 2018.
- Business Quant data shows FBRX's Non Operating Income at -$762000.0 in Q2 2018, -$34000.0 in Q1 2018, and -$150000.0 in Q4 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -139.24 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | -51.63 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | - |
| 10 | Forte Biosciences | 1.58 Bn | 1.23 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2018 | -762,000.00 |
| Mar 31, 2018 | -34,000.00 |
| Dec 31, 2017 | -150,000.00 |
| Sep 30, 2017 | -216,000.00 |
| Jun 30, 2017 | -414,000.00 |
| Mar 31, 2017 | -520,000.00 |
| Dec 31, 2016 | -456,000.00 |
| Sep 30, 2016 | -469,000.00 |
| Jun 30, 2016 | -422,000.00 |
| Mar 31, 2016 | -440,000.00 |